Bioavailability of Ubiquinol in Huntington Disease

University of Rochester

Status and phase: Completed; Phase 1

Conditions: Huntington Disease

Treatments: Dietary Supplement: ubiquinol

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00980694

UQ01

Details and patient eligibility

About

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have manifest Huntington disease
• Be 18 years of age or older
• Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
• Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion criteria

• Have a history of intolerability of sensitivity to CoQ
• Have an unstable medical or psychiatric illness
• Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Trial design

6 participants in 1 patient group

Ubiquinol

Experimental group

Description:

up to 600 mg per day, oral capsules for 8 weeks

Treatment:

Dietary Supplement: ubiquinol